Paola Tomei1, Valentina Masola1, Simona Granata1, Gloria Bellin1, Pierluigi Carratù2, Miriam Ficial3, Valentina Anna Ventura2, Maurizio Onisto4, Onofrio Resta2, Giovanni Gambaro5, Marco Chilosi3, Antonio Lupo1, Gianluigi Zaza6. 1. Department of Medicine, Renal Unit, University of Verona, Piazzale A. Stefani 1, 37126, Verona, VR, Italy. 2. Institute of Pulmonary Disease, University of Bari, Bari, Italy. 3. Department of Pathology and Diagnostic, Anatomic Pathology Section, University of Verona, Verona, Italy. 4. Department of Biomedical Sciences, University of Padova, Padua, Italy. 5. Division of Nephrology and Dialysis, School of Medicine Rome, Columbus-Gemelli Hospital Catholic University, Rome, Italy. 6. Department of Medicine, Renal Unit, University of Verona, Piazzale A. Stefani 1, 37126, Verona, VR, Italy. gianluigi.zaza@univr.it.
Abstract
BACKGROUND: Everolimus (EVE) is a mammalian target of rapamycin inhibitor (mTOR-I) widely used in transplantation that may determine some severe adverse events, including pulmonary fibrosis. The pathogenic mechanism of mTOR-I-associated pulmonary toxicity is still unclear, but epithelial to mesenchymal transition (EMT) of bronchial/pulmonary cells may play a role. METHODS: Three cell lines-human type II pneumocyte-derived A549, normal bronchial epithelial, and bronchial epithelial homozygous for the delta F508 cystic fibrosis-causing mutation-were treated with EVE or tacrolimus at different concentrations. Real-time polymerase chain reaction and immunofluorescence were used to evaluate mRNA and protein levels of EMT markers (alpha-SMA, vimentin, fibronectin). Subsequently, in 13 EVE- and 13 tacrolimus-treated patients we compared the rate of lung fibrosis, estimated by an arbitrary pulmonary fibrosis index score (PFIS). RESULTS: Biomolecular experiments demonstrated that high doses of EVE (100 nM) up-regulated EMT markers in all cell lines at both gene- and protein level. High concentrations of EVE were also able to reduce the mRNA levels of epithelial markers (E-cadherin and ZO-1) and to induce the phosphorylation of AKT. In the in vivo part of the study, PFIS was significantly higher in the EVE-group than the tacrolimus-group (p = 0.03) and correlated with trough levels (R2 = 0.35). CONCLUSIONS: Our data reveal, for the first time, a dose-dependent EVE-induced EMT in airway cells. They suggest that clinicians should employ, wherever possible, low dosages of mTOR-Is in transplant recipients, assessing periodically their pulmonary function.
BACKGROUND:Everolimus (EVE) is a mammalian target of rapamycin inhibitor (mTOR-I) widely used in transplantation that may determine some severe adverse events, including pulmonary fibrosis. The pathogenic mechanism of mTOR-I-associated pulmonary toxicity is still unclear, but epithelial to mesenchymal transition (EMT) of bronchial/pulmonary cells may play a role. METHODS: Three cell lines-human type II pneumocyte-derived A549, normal bronchial epithelial, and bronchial epithelial homozygous for the delta F508 cystic fibrosis-causing mutation-were treated with EVE or tacrolimus at different concentrations. Real-time polymerase chain reaction and immunofluorescence were used to evaluate mRNA and protein levels of EMT markers (alpha-SMA, vimentin, fibronectin). Subsequently, in 13 EVE- and 13 tacrolimus-treated patients we compared the rate of lung fibrosis, estimated by an arbitrary pulmonary fibrosis index score (PFIS). RESULTS: Biomolecular experiments demonstrated that high doses of EVE (100 nM) up-regulated EMT markers in all cell lines at both gene- and protein level. High concentrations of EVE were also able to reduce the mRNA levels of epithelial markers (E-cadherin and ZO-1) and to induce the phosphorylation of AKT. In the in vivo part of the study, PFIS was significantly higher in the EVE-group than the tacrolimus-group (p = 0.03) and correlated with trough levels (R2 = 0.35). CONCLUSIONS: Our data reveal, for the first time, a dose-dependent EVE-induced EMT in airway cells. They suggest that clinicians should employ, wherever possible, low dosages of mTOR-Is in transplant recipients, assessing periodically their pulmonary function.
Authors: Dos D Sarbassov; Siraj M Ali; Shomit Sengupta; Joon-Ho Sheen; Peggy P Hsu; Alex F Bagley; Andrew L Markhard; David M Sabatini Journal: Mol Cell Date: 2006-04-06 Impact factor: 17.970
Authors: Phuong-Thu T Pham; Phuong-Chi T Pham; Gabriel M Danovitch; David J Ross; H Albin Gritsch; Elizabeth A Kendrick; Jennifer Singer; Tariq Shah; Alan H Wilkinson Journal: Transplantation Date: 2004-04-27 Impact factor: 4.939
Authors: Simona Alexandru; Alberto Ortiz; Sonia Baldovi; Jose Maria Milicua; Elena Ruíz-Escribano; Jesús Egido; Juan José Plaza Journal: Nephrol Dial Transplant Date: 2008-07-25 Impact factor: 5.992
Authors: S Lupinacci; G Toteda; D Vizza; A Perri; C Benincasa; A Mollica; A La Russa; P Gigliotti; F Leone; D Lofaro; M Bonofiglio; E Perri; R Bonofiglio Journal: J Nephrol Date: 2016-12-02 Impact factor: 3.902